NasdaqGS:NVAXBiotechs
Novavax (NVAX) Is Down 11.4% After Sanofi Vaccine Deal and Q3 Results - Has the Narrative Shifted?
In November 2025, Novavax completed the transfer of U.S. marketing authorization for its COVID-19 vaccine to Sanofi and reported third quarter results, which included revenue of US$70.45 million and a net loss of US$202.38 million for the quarter, but net income of US$422.78 million for the nine months ended September 30, 2025.
This collaboration with Sanofi not only delivered a US$25 million milestone payment to Novavax, but also positions the company for future milestone and royalty...